Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc.（RIGL）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · RIGL · 截至 2026年6月8日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
2
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
Rigel Pharmaceuticals, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
RIGL 季度内部人买卖趋势
RIGL 内幕交易卖出 · RIGL 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · RIGL CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
RIGL 高管卖出股份 · RIGL 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Jun 1, 2026 | Schorno Dean L EVP & Chief Financial Officer | Option | 2,181 | $28K | Form 4 |
| Jun 1, 2026 | Schorno Dean L EVP & Chief Financial Officer | Other | 928 | $28K | Form 4 |
| Jun 1, 2026 | Schorno Dean L EVP & Chief Financial Officer | Option | 1,200 | $22K | Form 4 |
| Jun 1, 2026 | Santos David A EVP, Chief Commercial Officer | Other | 874 | $26K | Form 4 |
| Jun 1, 2026 | Rojkjaer Lisa EVP, Chief Medical Officer | Other | 850 | $25K | Form 4 |
| Jun 1, 2026 | RODRIGUEZ RAUL R CEO, President · Director | Other | 2,424 | $72K | Form 4 |
| Jun 1, 2026 | Furey Raymond J. EVP, GC, CCO & Corp Sec | Other | 877 | $26K | Form 4 |
| May 26, 2026 | Ali-Jackson Kamil Director | Sale | 2,500 | $73K | Form 4 |
| May 15, 2026 | Wasman Jane Director | Award | 5,750 | — | Form 4 |
| May 15, 2026 | MOOS WALTER H Director | Award | 5,750 | — | Form 4 |
| May 15, 2026 | MILLER MICHAEL PATRICK Director | Award | 5,750 | — | Form 4 |
| May 15, 2026 | LAPOINTE ANTHONY GREGG Director | Award | 5,750 | — | Form 4 |
| May 15, 2026 | HANNAH ALISON L. Director | Award | 5,750 | — | Form 4 |
| May 15, 2026 | Frohlich Mark W Director | Award | 5,750 | — | Form 4 |
| May 15, 2026 | Ali-Jackson Kamil Director | Award | 5,750 | — | Form 4 |
| Feb 20, 2026 | MOOS WALTER H Director | Option | 4,000 | $96K | Form 4 |
| Feb 20, 2026 | MOOS WALTER H Director | Sale | 4,000 | $145K | Form 4 |
| Feb 17, 2026 | Furey Raymond J. EVP, GC, CCO & Corp Sec | Award | 19,497 | — | Form 4 |
| Feb 17, 2026 | RODRIGUEZ RAUL R CEO, President · Director | Award | 53,915 | — | Form 4 |
| Feb 17, 2026 | Rojkjaer Lisa EVP, Chief Medical Officer | Award | 18,894 | — | Form 4 |
| Feb 17, 2026 | Schorno Dean L EVP & Chief Financial Officer | Award | 20,636 | — | Form 4 |
| Feb 17, 2026 | Santos David A EVP, Chief Commercial Officer | Award | 19,430 | — | Form 4 |
| Feb 10, 2026 | Schorno Dean L EVP & Chief Financial Officer | Other | 3,546 | $123K | Form 4 |
| Feb 10, 2026 | Furey Raymond J. EVP, GC, CCO & Corp Sec | Other | 3,546 | $123K | Form 4 |
| Feb 10, 2026 | Santos David A EVP, Chief Commercial Officer | Other | 3,546 | $123K | Form 4 |
Schorno Dean L
EVP & Chief Financial Officer
日期
Jun 1
股数
2,181
均价
$12.70
总金额
$28K
Schorno Dean L
EVP & Chief Financial Officer
日期
Jun 1
股数
1,200
均价
$18.70
总金额
$22K
Schorno Dean L
EVP & Chief Financial Officer
日期
Feb 10
股数
3,546
均价
$34.62
总金额
$123K
Santos David A
EVP, Chief Commercial Officer
日期
Feb 10
股数
3,546
均价
$34.62
总金额
$123K
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 RIGL 内幕交易
RIGL 内幕交易
Rigel Pharmaceuticals, Inc.（RIGL）内幕交易数据来源于公司内部人（包括Schorno Dean L (EVP & Chief Financial Officer), RODRIGUEZ RAUL R (CEO, President · Director), Santos David A (EVP, Chief Commercial Officer)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。RIGL内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Rigel Pharmaceuticals, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
RIGL 内幕交易 · 5个问题Rigel Pharmaceuticals, Inc.（RIGL）的内部人包括高管和董事，如Schorno Dean L (EVP & Chief Financial Officer), RODRIGUEZ RAUL R (CEO, President · Director), Santos David A (EVP, Chief Commercial Officer)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026